AbbVie announced the launch of Produodopa in the European Union for the treatment of advanced Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia, and when available combinations of Parkinson’s medicinal products have not given satisfactory results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABBV:
- AbbVie and Umoja Biopharma partnering to develop in-situ CAR-T cell therapies
- CVS Caremark accelerates biosimilars adoption through formulary changes
- AbbVie Stock (NASDAQ:ABBV): Goodbye Wrinkles, Hello Profits
- AbbVie price target lowered to $180 from $195 at Wells Fargo
- Cerevel Therapeutics price target raised to $45 from $25 at JPMorgan
